ATNM
Price
$1.66
Change
+$0.08 (+5.10%)
Updated
Jul 31, 04:59 PM (EDT)
Capitalization
48.98M
115 days until earnings call
CLVLY
Price
$8.14
Change
+$0.19 (+2.39%)
Updated
Jul 30 closing price
Capitalization
423.36M
Interact to see
Advertisement

ATNM vs CLVLY

Header iconATNM vs CLVLY Comparison
Open Charts ATNM vs CLVLYBanner chart's image
Actinium Pharmaceuticals
Price$1.66
Change+$0.08 (+5.10%)
Volume$900
Capitalization48.98M
Clinuvel Pharmaceuticals
Price$8.14
Change+$0.19 (+2.39%)
Volume$2.18K
Capitalization423.36M
ATNM vs CLVLY Comparison Chart in %
Loading...
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLVLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATNM vs. CLVLY commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a StrongBuy and CLVLY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (ATNM: $1.63 vs. CLVLY: $8.26)
Brand notoriety: ATNM and CLVLY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 165% vs. CLVLY: 136%
Market capitalization -- ATNM: $48.98M vs. CLVLY: $423.36M
ATNM [@Biotechnology] is valued at $48.98M. CLVLY’s [@Biotechnology] market capitalization is $423.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $223.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 0 FA rating(s) are green whileCLVLY’s FA Score has 1 green FA rating(s).

  • ATNM’s FA Score: 0 green, 5 red.
  • CLVLY’s FA Score: 1 green, 4 red.
According to our system of comparison, CLVLY is a better buy in the long-term than ATNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 6 TA indicator(s) are bullish while CLVLY’s TA Score has 6 bullish TA indicator(s).

  • ATNM’s TA Score: 6 bullish, 4 bearish.
  • CLVLY’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ATNM is a better buy in the short-term than CLVLY.

Price Growth

ATNM (@Biotechnology) experienced а -10.44% price change this week, while CLVLY (@Biotechnology) price change was +8.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.13%. For the same industry, the average monthly price growth was +16.53%, and the average quarterly price growth was +40.85%.

Reported Earning Dates

ATNM is expected to report earnings on Nov 24, 2025.

CLVLY is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-1.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLVLY($423M) has a higher market cap than ATNM($49M). ATNM YTD gains are higher at: 29.365 vs. CLVLY (7.208). CLVLY has higher annual earnings (EBITDA): 63.4M vs. ATNM (-48.36M). CLVLY has higher revenues than ATNM: CLVLY (91.6M) vs ATNM (0).
ATNMCLVLYATNM / CLVLY
Capitalization49M423M12%
EBITDA-48.36M63.4M-76%
Gain YTD29.3657.208407%
P/E RatioN/A16.55-
Revenue091.6M-
Total Cash65.3MN/A-
Total Debt1.43MN/A-
FUNDAMENTALS RATINGS
ATNM vs CLVLY: Fundamental Ratings
ATNM
CLVLY
OUTLOOK RATING
1..100
739
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9845
PRICE GROWTH RATING
1..100
5349
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
1350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLVLY's Valuation (4) in the null industry is significantly better than the same rating for ATNM (72) in the Biotechnology industry. This means that CLVLY’s stock grew significantly faster than ATNM’s over the last 12 months.

CLVLY's Profit vs Risk Rating (100) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ATNM’s over the last 12 months.

CLVLY's SMR Rating (45) in the null industry is somewhat better than the same rating for ATNM (98) in the Biotechnology industry. This means that CLVLY’s stock grew somewhat faster than ATNM’s over the last 12 months.

CLVLY's Price Growth Rating (49) in the null industry is in the same range as ATNM (53) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ATNM’s over the last 12 months.

CLVLY's P/E Growth Rating (90) in the null industry is in the same range as ATNM (100) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ATNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATNMCLVLY
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 2 days ago
54%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 2 days ago
61%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 2 days ago
58%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 8 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
ATNM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLVLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WAMFX23.82N/A
N/A
Boston Trust Walden Midcap
SEVIX14.66N/A
N/A
SEI US Managed Volatility I (SIMT)
ATEYX167.87N/A
N/A
AB Sustainable Global Thematic Advisor
JEPAX14.06N/A
N/A
JPMorgan Equity Premium Income A
EEIFX9.82N/A
N/A
Monteagle Enhanced Equity Income Instl

CLVLY and

Correlation & Price change

A.I.dvisor tells us that CLVLY and ADAP have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLVLY and ADAP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLVLY
1D Price
Change %
CLVLY100%
+1.41%
ADAP - CLVLY
22%
Poorly correlated
-19.68%
QLGN - CLVLY
21%
Poorly correlated
-11.33%
ATNM - CLVLY
20%
Poorly correlated
+3.82%
BSEM - CLVLY
11%
Poorly correlated
+3.82%
CMXHF - CLVLY
10%
Poorly correlated
-0.57%
More